A Multiple-Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3305677 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 10 Nov 2017
At a glance
- Drugs LY 3305677 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Eli Lilly
- 01 Nov 2017 Planned End Date changed from 1 Jun 2018 to 1 Aug 2018.
- 01 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Aug 2018.
- 01 Nov 2017 Status changed from not yet recruiting to recruiting.